Methotrexate as single therapy in Crohn's disease: Is its long-term efficacy limited?

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 2, 2008, Pages 153-157

  Charpignon, C ^a   Beau, P ^a  

^a University of Poitiers   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; DIPYRONE; FOLIC ACID; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ABDOMINAL PAIN; ADULT; APLASIA; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; REMISSION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; COHORT STUDIES; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 43049108076     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2007.11.011     Document Type: Article

References (30)

1. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332 (1995) 292-297
2. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 (2000) 1627-1632
3. Ardizzone S., Bollani S., Manzionna G., Imbesi V., Colombo E., and Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 35 (2003) 619-627
4. Soon S.Y., Azhar A., May Y., Raoof S., Hirst J., and Sanderson J.D. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 16 (2004) 921-926
5. Mahadevan U., Marion J.F., and Present D.H. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther 18 (2003) 1003-1008
6. Topstad D.R., Panaccione R., Heine J.A., Johnson D.R., MacLean A.R., and Buie W.D. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 46 (2003) 577-583
7. Lémann M. Méthotrexate : l'oublié. POST'U FMC-HGE 2006:9-14.
8. Kozarek R.A. Long-term treatment of Crohn's disease with methotrexate, or, why's a nice drug like you still a wannabe in the treatment in the inflammatory bowel disease?. Am J Gastroenterol 95 (2000) 1619-1620
9. Korelitz B.I. Is there any remaining role for methotrexate for Crohn's disease?. Dig Liver Dis 35 (2003) 610-611
10. Beaugerie L., Carrat F., Bouvier A.M., Brousse N., Carbonnel F., Colombel J.F., et al. Cohorte nationale CESAME (Cancers et sur-risque associé aux maladies inflammatoires chroniques intestinales En France) : données démographiques et médicales 2004-2005 pour 20 919 patients. Gastroenterol Clin Biol 29 (2005) A155
11. Lemann M., Zenjari T., Bouhnik Y., Cosnes J., Mesnard B., Rambaud J.C., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 95 (2000) 1730-1734
12. Chong R.Y., Hanauer S.B., and Cohen R.D. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 15 (2001) 35-44
13. Vandeputte L., D'Haens G., Baert F., and Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 5 (1999) 11-15
14. Harvey R.F., and Bradshaw J.M. Measuring Crohn's disease activity. Lancet 24 (1980) 1134-1135
15. Blanchet E., Beau P., and Frat J.P. Aplasie médullaire après prise de noramidopyrine chez une patiente traitée au long cours par méthotrexate pour maladie de Crohn. Gastroenterol Clin Biol 28 (2004) 502-503
16. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., and Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110 (1989) 353-356
17. Baron T.H., Truss C.D., and Elson C.O. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 38 (1993) 1851-1856
18. Lemann M., Chamiot-Prieur C., Mesnard B., Halphen M., Messing B., Rambaud J.C., et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 10 (1996) 309-314
19. Kurnik D., Loebstein R., Fishbein E., Almog S., Halkin H., Bar-Meir S., et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 18 (2003) 57-63
20. Arora S., Katkov W., Cooley J., Kemp J.A., Johnston D.E., Schapiro R.H., et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 46 (1999) 1724-1729
21. Oren R., Moshkowitz M., Odes S., Becker S., Keter D., Pomeranz I., et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomised, Israeli multicenter trial. Am J Gastroenterol 92 (1997) 2203-2209
22. Egan L.J., Sandborn W.J., Tremaine W.J., Leighton J.A., Mays D.C., Pike M.G., et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 13 (1999) 1597-1604
23. Schröder O., and Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 98 (2003) 530-537
24. Laharie D., Zerbib F., Adhoute X., Boué-Lahorgue X., Foucher J., Castéra L., et al. Diagnosis of liver fibrosis by transient elastography (Fibroscan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 23 (2006) 1621-1628
25. Te H.S., Schiano T.D., Kuan S.F., Hanauer S.B., Conjeevaram H.S., and Baker A.L. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 95 (2000) 3150-3156
26. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Screiber S., Colombel J.F., et al. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
27. Smolen J.S., Van Der Heijde D.M., St Clair E.W., Emery P., Bathon J.M., Keyston E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54 (2006) 702-710
28. Van den Brande J.M., Peppelenbosch M.P., and Hommes D.W. Synergistic effect of methotrexate and infliximab on activated lymphocyte apoptosis. Inflamm Bowel Dis 13 (2007) 118-119
29. Hommes D. Discussion on predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 124 (2003) 2002-2003
30. Vermeire S., Noman M., van Assche G., Baert F., D'Haens G., and Rutgeerts P.J. The effectiveness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231